Thymosin Alpha-1 Kit
Price range: $110.00 through $210.00
References: Product information from 39.net drug database; supplier specifications (Biomart.cn); clinical applications in chronic hepatitis B treatment (as per 日达仙®说明书); immunomodulatory mechanisms in infectious disease research.
Description
🧪 Product Profile: Thymosin Alpha-1
Product Name: Thymosin Alpha-1
CAS Number: 62304-98-7
Molecular Formula: C₁₂₉H₂₁₅N₃₃O₅₅
Molecular Weight: 3108.37 g/mol
Amino Acid Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
Purity: ≥98% (HPLC verified)
Formulation: Lyophilized powder (standard vials: 1.6mg, 3.2mg)
🔬 Key Characteristics
Thymosin Alpha-1 is a synthetic peptide corresponding to the N-terminal 28-amino acid fragment of thymosin α1, a naturally occurring thymic hormone. It is characterized by an acetylated N-terminus and multiple acidic residues (Asp, Glu), which contribute to its stability and biological activity. As a highly conserved peptide, it exhibits cross-species activity and is resistant to proteolytic degradation, making it suitable for therapeutic and research applications.
⚙️ Mechanism of Action
- Immunomodulation: Enhances T-cell maturation and differentiation, particularly promoting the development of naive T-cells into cytotoxic T-lymphocytes (CTLs) and helper T-cells (Th1/Th2).
- Cytokine Regulation: Stimulates the production of interferon-α, interleukin-2 (IL-2), and tumor necrosis factor-α (TNF-α), thereby boosting innate and adaptive immune responses.
- Antigen Presentation: Improves dendritic cell function, facilitating the presentation of antigens to T-cells and enhancing immune surveillance against viral infections and tumors.
- Anti-inflammatory Activity: Modulates the balance between pro-inflammatory and anti-inflammatory cytokines, reducing excessive immune activation while maintaining pathogen-specific responses.
📊 Research Applications
- Infectious Diseases: Studies on chronic viral infections (e.g., hepatitis B, hepatitis C, HIV) to enhance antiviral immune responses.
- Oncology: Investigation of immunotherapeutic strategies for cancer, including combination therapy with checkpoint inhibitors or vaccines.
- Immunodeficiency Disorders: Research on primary and secondary immunodeficiencies, such as those associated with aging, chemotherapy, or chronic illness.
- Vaccine Adjuvant: Evaluation of its ability to enhance the efficacy of viral vaccines (e.g., influenza, hepatitis B) in immunocompromised individuals.
💡 Product Features
- Stability: Lyophilized form stable for 24 months at 2-8°C; reconstituted solutions (with sterile water) stable for 24 hours at room temperature or 7 days under refrigeration.
- Administration: Typically administered via subcutaneous injection, with a recommended dosage of 1.6mg twice weekly for immune enhancement.
- Safety Profile: Low toxicity with minimal side effects, primarily mild injection site reactions (e.g., redness, swelling).
- Clinical Relevance: Approved in multiple countries for the treatment of chronic hepatitis B and as an immune booster in cancer patients undergoing chemotherapy.
⚠️ Disclaimer
For Research Use Only: Not approved for human clinical use in all jurisdictions. Handling requires compliance with peptide research protocols, including proper reconstitution and disposal of contaminated materials.
Additional information
| FORMAT | 10Bottlex5mg, 10Bottlex10mg |
|---|




